Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kevin Fitzgerald

Urology Doylestown, PA Medical Doctor

NPI 1225033582 CMS profile 282575

102 Progress Dr, Suite 101, Doylestown, PA 18901

Open in the dashboard

General payments

$5,891

284 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kevin Fitzgerald of Doylestown, PA is reported in the CMS Open Payments database as having received $5,891 across 284 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $266 12
2024 General $1,333 64
2023 General $1,395 58
2022 General $734 42
2021 General $887 47
2020 General $409 21
2019 General $868 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Fitzgerald
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Kevin Fitzgerald were reported at $266. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Kevin Fitzgerald Urology median Middle half National median
2019 $868 $480 $147–$1,201 $163
2020 $409 $246 $87–$645 $114
2021 $887 $358 $111–$1,000 $132
2022 $734 $476 $143–$1,263 $149
2023 $1,395 $560 $168–$1,461 $160
2024 $1,333 $563 $170–$1,464 $164
2025 $266 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $718 41 payments
  2. AbbVie, Inc. $637 36 payments
  3. Boston Scientific Corporation $432 16 payments
  4. Sumitomo Pharma America, Inc. $346 21 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $319 13 payments
  6. Intuitive Surgical, Inc. $254 5 payments
  7. Medtronic, Inc. $248 10 payments
  8. Teleflex LLC $223 11 payments
  9. 180 Medical, Inc. $199 8 payments
  10. Urovant Sciences Inc $162 7 payments
  11. Other $2,353 116 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,691 282 payments
  2. Education $200 2 payments
Products named General payments · program years 2019–2025
  1. GEMTESA $462 25 payments
  2. XTANDI $336 21 payments
  3. Xofigo $319 13 payments
  4. Nubeqa $297 12 payments
  5. MYRBETRIQ $288 24 payments
  6. LUPRON DEPOT $280 18 payments
  7. Da Vinci Surgical System $254 5 payments
  8. INTERSTIM $248 10 payments
  9. BOTOX $226 11 payments
  10. UROLIFT $185 9 payments
  11. Other $3,453 164 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

2,172

Median for Urology: 1,053

Drug cost

$140,630

Median for Urology: $101,464

Branded share of claims

16.3%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 70 $36,896
Gemtesa Vibegron Brand 43 $36,189
Finasteride Generic 722 $13,656
Methenamine Hippurate Generic 82 $9,671
Tamsulosin Hcl Generic 471 $8,194
Trospium Chloride Er Trospium Chloride Brand 25 $6,116
Dutasteride Generic 118 $5,155
Silodosin Generic 36 $4,723
Solifenacin Succinate Generic 141 $4,689
Potassium Citrate Er Potassium Citrate Brand 45 $3,775

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$139,556

Of which drugs: $11,797

Medicare patients

608

Average age 75

Services billed

2,122

48 women, 560 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Cancer 33%
Ischemic heart disease 31%
Diabetes 25%
Atrial fibrillation 23%
Chronic kidney disease 23%
Depression 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $181
$181 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $167
$167 43 —
JELMYTO
  • UROGEN PHARMA, INC. $71
$71 — —
POSLUMA
  • Blue Earth Diagnostics Limited $56
$56 — —
LUPRON DEPOT
  • AbbVie, Inc. $50
$50 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

284 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record